Inventor · disambiguated record
Bryan Irving
Also filed as: IRVING BRYAN · IRVING BRYAN A · IRVING BRYAN ALLEN
15 granted patents·29 pending applications·1,493 citations·filing 2001–2025
94Inventor score
Files withGENENTECH INC26CYTOMX THERAPEUTICS INC8AMUNIX PHARMACEUTICALS INC3ARBOR VITA CORP1BRENNAN JANE1
Top patents by PatentIndex Score
44 records- 0196US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 0296US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 0396US9920123B2Anti-PD-L1 antibodies, compositions and articles of manufactureGENENTECH INC·Filed 2016·Granted Mar 20, 2018·30 cites·30 claims
- 0495US10626174B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2016·Granted Apr 21, 2020·10 cites·22 claims
- 0595US10611836B2Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2016·Granted Apr 7, 2020·9 cites·12 claims
- 0695US8217149B2Anti-PD-L1 antibodies, compositions and articles of manufactureIRVING BRYAN·Filed 2009·Granted Jul 10, 2012·1.3k cites·61 claims
- 0794US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 0894US9873740B2Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitorsGENENTECH INC·Filed 2014·Granted Jan 23, 2018·26 cites·13 claims
- 0992US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 1092US9724413B2Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitorsMAECKER HEATHER·Filed 2012·Granted Aug 8, 2017·43 cites·33 claims
- 1190US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 1286US10646567B2Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitorsGENENTECH INC·Filed 2017·Granted May 12, 2020·2 cites·30 claims
- 1385US2024166741A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2023·Application pending·0 cites
- 1485US2023287127A1Anti-pd-l1 antibodies, compositions and articles of manufactureGENENTECH INC·Filed 2023·Application pending·0 cites
- 1582US11802158B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·1 cites·21 claims
- 1678US2025382370A1Anti-pd-l1 antibodies, compositions and articles of manufactureGENENTECH INC·Filed 2025·Application pending·0 cites
- 1777US12215156B2HER-2 targeted bispecific compositions and methods for making and using the sameAMUNIX PHARMACEUTICALS INC·Filed 2023·Granted Feb 4, 2025·0 cites·8 claims
- 1877US2024084010A1Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1976US9895441B2Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonistsGENENTECH INC·Filed 2014·Granted Feb 20, 2018·2 cites·10 claims
- 2076US2021340253A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2176US2021332132A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2021·Application pending·0 cites
- 2273US2021032345A1Anti-pd-l1 antibodies, compositions and articles of manufactureGENENTECH INC·Filed 2020·Application pending·0 cites
- 2371US2020399366A1Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsGENENTECH INC·Filed 2020·Application pending·0 cites
- 2471US2022362378A1Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonistsGENENTECH INC·Filed 2022·Application pending·0 cites
- 2567US2015322153A1Anti-pd-l1 antibodies and articles of manufactureGENENTECH INC·Filed 2014·Application pending·0 cites
- 2667US2019016807A1Anti-pd-l1 antibodies, compositions and articles of manufactureGENENTECH INC·Filed 2018·Application pending·0 cites
- 2765US2014065135A1Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunityGENENTECH INC·Filed 2013·Application pending·0 cites
- 2863US2017008971A1Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodiesGENENTECH INC·Filed 2016·Application pending·0 cites
- 2962US2013045202A1Anti-pd-l1 antibodies and articles of manufactureGENENTECH INC·Filed 2012·Application pending·0 cites
- 3062US2013045201A1Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunityGENENTECH INC·Filed 2012·Application pending·0 cites
- 3162US2013045200A1Methods of using anti-pd-l1 antibodies and their use to treat infection resulting from t-cell dysfunctionGENENTECH INC·Filed 2012·Application pending·0 cites
- 3262US2023322922A1Her-2 targeted bispecific compositions and methods for making and using the sameAMUNIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3361US2021238291A1Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3460US2008279848A1Methods of treating lupus using CD4 antibodiesGENENTECH INC·Filed 2008·Application pending·0 cites
- 3560US2016222117A1Nucleic acid encoding anti-pd-l1 antibodiesGENENTECH INC·Filed 2015·Application pending·0 cites
- 3658US2023265146A1Cytokine conjugatesAMUNIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3754US2018236066A1Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonistsGENENTECH INC·Filed 2018·Application pending·0 cites
- 3850US2009293137A1Novel Gene Disruptions, Compositions and Methods Relating TheretoGENENTECH INC·Filed 2006·Application pending·0 cites
- 3948US2003049695A1PDZ domain interactions and lipid raftsFiled 2002·Application pending·0 cites
- 4047US2010215677A1Pdz domain interactions and lipid raftsARBOR VITA CORP·Filed 2010·Application pending·0 cites
- 4146US2007218062A1Methods of treating lupus using CD4 antibodiesGENENTECH INC·Filed 2007·Application pending·0 cites
- 4243US2002111474A1Chimeric chains for receptor-associated signal transduction pathwaysFiled 2001·Application pending·0 cites
- 4341US2011182883A1Novel gene disruptions, compositions and methods relating theretoCOMBS KATHERIN E·Filed 2011·Application pending·0 cites
- 4440US2008305106A1Novel Gene Disruptions, Composition and Methods Relating TheretoBRENNAN JANE·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →